There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.
In August of last year, the company announced a new position, Chief Digital Officer, and the man to take the position, in Bertrand Bodson.
read more http://www.pharmafile.com/news/517158/novartis-forges-forward-digital-pharma-focalview-app
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients. http://drugdiscovery.pharmaceutical-business-review.com/news/sandoz-pear-to-develop-digital-therapeutics-for-substance-use-disorder-190418-6121611
Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/
AstraZeneca has licensed a NASH candidate from Ionis. The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic. https://www.fiercebiotech.com/biotech/astrazeneca-licenses-ionis-clinical-phase-antisense-nash-drug
Novartis is expanding its strategic alliance with Science 37 and has committed to conducting up to 10 new clinical trials â blending both virtual and traditional models â over the next three years. https://www.outsourcing-pharma.com/Article/2018/03/07/Novartis-scaling-site-less-trials-through-expanded-Science-37-alliance
Viela Bio will launch with $250 million in funding to support development of the six biologics from AstraZeneca’s MedImmune arm. https://www.biopharmadive.com/news/astrazeneca-medimmune-spins-out-autoimmune-drugs-launches-viela-bio/518058/
Swiss pharma giant Roche is buying Flatiron, which was founded by two ex-Google employees and aims to improve cancer treatment. https://www.cnbc.com/2018/02/15/roche-buying-flatiron-health-backed-by-alphabet.html
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases. http://www.topix.com/business/pharmaceuticals/2018/01/frances-sanofi-buys-us-hemophilia-specialist-bioverativ?fromrss=1
The conversations may be about Amazon taking a role in drug purchasing, competing against distributors like McKesson, AmerisourceBergen, and Cardinal Health. https://www.biospace.com/article/around-the-web/amazon-in-exploratory-talks-with-mylan-novartis-about-pharma-entry-/